Cite

    Antonio M Risitano et al.. “Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal haemoglobinuria and active haemolysis: an open-label, single-arm, phase 2, proof-of-concept trial.” Lancet, vol. 8, no. 5, 2021, pp. e344–e354. http://access.bl.uk/ark:/81055/vdc_100129512596.0x000003